title: Identifying, evaluating, and controlling bioanalytical risks resulting from nonuniform matrix ion suppression/enhancement and nonlinear liquid chromatography-mass spectrometry assay response.
authors.affiliation: Bioanalytical Sciences, Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543, USA. Guowen.liu@bms.com
authors.forename: Guowen
authors.initials: G
authors.lastname: Liu
authors.forename: Qin C
authors.initials: QC
authors.lastname: Ji
authors.forename: Mark E
authors.initials: ME
authors.lastname: Arnold
mesh_terms: D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D009853:Omeprazole / Q000592:standards / Q000652:urine*; D011786:Quality Control; D012044:Regression Analysis; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods* / Q000592:standards
chemical_list: D009853:Omeprazole